Stock EMMLD OKYO PHARMA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News OKYO Pharma Limited

Equities

EMMLD

GG00BMFG5F62

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-07-02 pm EDT 		5-day change 1st Jan Change
1.21 USD -2.42% Intraday chart for OKYO Pharma Limited +4.31% -31.64%
Mar. 22 H.C. Wainwright Adjusts Price Target on OKYO Pharma to $7 From $6, Maintains Buy Rating MT
Mar. 22 OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
OKYO Pharma Announces Participation in May 2024 Investor Conferences
AQ
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
AQ
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
AQ
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
AQ
H.C. Wainwright Adjusts Price Target on OKYO Pharma to $7 From $6, Maintains Buy Rating
MT
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
AQ
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
CI
OKYO Pharma Limited to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
CI
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
AQ
Sector Update: Health Care Stocks Mixed in Afternoon Trading
MT
Sector Update: Health Care
MT
OKYO Pharma Rising After FDA Approves Phase 2 Trial of Prospective Treatment for Cornea Eye Pain
MT
Okyo Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
CI
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
AQ
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board
AQ
OKYO Pharma Limited Announces Appointment of Scientific Advisory Board
CI
OKYO Pharma Limited Reports Positive Safety and Efficacy Results in Its Phase 2, Randomized, Double-Masted, Placebo-Controlled Trial Evaluating the Safety and Efficacy of OK-101 Ophthalmic Solution in Patients with Dry Eye Disease
CI
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease
AQ
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
AQ
OKYO PHARSADR : INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K - Form 6-K
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EMMLD Stock
  4. News OKYO Pharma Limited